Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Abstract: Disclosed are a shield tunnel segment structure and a construction method thereof. The shield tunnel segment structure includes segment blocks sequentially spliced in a circumferential direction. Each segment block forms a closed annular segment structure, and outer diameters of adjacent annular segment structures gradually increase in an axial direction. At least two adjacent segment blocks of the same annular segment structure form an annular inner groove, and at least one segment block of the adjacent annular segment structures is provided with an inner bump which matches the annular inner groove. At least two adjacent segment blocks of the same annular segment structure form an annular outer groove, and at least one segment block of the adjacent annular segment structures is provided with an outer bump which matches the annular outer groove. The annular outer grooves and the annular inner grooves are staggered in the circumferential direction.

Abstract: The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.

Abstract: The present disclosure relates to gallium-based dehydrogenation catalysts that further include additional metal components, and to methods for dehydrogenating hydrocarbons using such catalysts. One aspect of the disclosure provides a calcined dehydrogenation catalyst that includes a gallium species, a cerium species, a platinum promoter, and a silica-alumina support. Optionally, the composition can include a promoter selected from the alkali metals and alkaline earth metals.

Abstract: The present disclosure relates to mixed-bed systems comprising a particulate dehydrogenation catalyst based on one or more certain group 13 and 14 elements that further include additional metal components and a particulate non-catalytic additive comprising a heat-generating material, and to methods for dehydrogenating hydrocarbons using such systems. One aspect of the disclosure provides a mixed-bed system comprising a particulate dehydrogenation catalyst and a particulate non-catalytic additive. The particulate dehydrogenation catalyst includes a primary species P1 selected from Ga, In, TI, Ge, Sn Pb, and any mixture thereof; a primary species P2 selected from the lanthanides and any mixture thereof; a promoter M1 selected from Ni, Pd, Pt, La, Ir, Zn, Fe, Rh, Ru, Mn, Co, W, and any mixture thereof; and a promoter M2 selected from Li, Na, K, Rb, Cs, Be, Mg, Ca, Sr, Ba, and any mixture thereof on a support S1 selected from silica, alumina, zirconia, titania, yttria, and any mixture thereof.

Abstract: The present disclosure relates to gallium-based dehydrogenation catalysts that further include additional metal components, and to methods for dehydrogenating hydrocarbons using such catalysts. One aspect of the disclosure provides a calcined dehydrogenation catalyst that includes a gallium species, a cerium species, a platinum promoter, and a silica-alumina support. Optionally, the composition can include a promoter selected from the alkali metals and alkaline earth metals.

Abstract: This disclosure relates to catalysts comprising gallium, cerium, and a mixed oxide support useful in the dehydrogenation of hydrocarbons, to methods for making such catalysts, and to methods for dehydrogenating hydrocarbons with such catalysts. For example, in one embodiment, a catalyst composition includes gallium oxide, present in the composition in an amount within the range of about 0.1 wt. % to about 30 wt. %, cerium oxide, present in the composition in an amount within the range of about 0.1 wt. % to about 15 wt. %, a promoter, M1, selected from Pt, Ir, La, or a mixture thereof, present in the composition in an amount within the range of about 0.005 wt. % to about 4 wt. %, a promoter, M2, selected from the group 1 elements (e.g., Li, Na, K, Cs), present in the composition in an amount within the range of about 0.05 wt. % to about 3 wt. %, and a support, S1, selected from alumina, silica, zirconia, titania, or a mixture thereof, present in the composition in an amount within the range of about 60 wt.

Abstract: The present disclosure relates to dehydrogenation catalysts based on one or more certain group 13 and group 14 elements that further include additional metal components, to methods for making such catalysts, and to methods for dehydrogenating hydrocarbons using such catalysts. One aspect of the disclosure provides a calcined dehydrogenation catalyst that includes a primary species P1 selected from the group consisting of Ga, In, Tl, Ge, Sn and Pb and combinations thereof; a primary species P2 selected from the lanthanides; a promoter M1 selected from the group consisting of Ni, Pd and Pt; a promoter M2 selected from the group consisting of Li, Na, K, Rb, Cs, Be, Mg, Ca, Sr and Ba, on a silica-alumina support.

Abstract: This disclosure relates to catalyst compositions including gallium and a zirconium-based mixed oxide support, to methods for making such catalysts, and to methods for dehydrogenating hydrocarbons with such catalysts. For example, in one embodiment, a catalyst composition includes a mixed oxide support comprising at least about 50 wt. % of zirconium oxide, the mixed oxide support being present in the composition in an amount within the range of about 40 wt. % to about 99.9 wt. %; and disposed on the support, gallium, present in the composition in an amount within the range of about 0.1 wt. % to about 30 wt. %, calculated as Ga2O3 on a calcined basis.

Abstract: This disclosure relates to catalysts comprising gallium, cerium, and a mixed oxide support useful in the dehydrogenation of hydrocarbons, to methods for making such catalysts, and to methods for dehydrogenating hydrocarbons with such catalysts. For example, in one embodiment, a catalyst composition includes gallium oxide, present in the composition in an amount within the range of about 0.1 wt. % to about 30 wt. %, cerium oxide, present in the composition in an amount within the range of about 0.1 wt. % to about 15 wt. %, a promoter, M1, selected from Pt, Ir, La, or a mixture thereof, present in the composition in an amount within the range of about 0.005 wt. % to about 4 wt. %, a promoter, M2, selected from the group 1 elements (e.g., Li, Na, K, Cs), present in the composition in an amount within the range of about 0.05 wt. % to about 3 wt. %, and a support, S1, selected from alumina, silica, zirconia, titania, or a mixture thereof, present in the composition in an amount within the range of about 60 wt.

Abstract: The present disclosure relates to dehydrogenation catalysts based on one or more certain group 13 and group 14 elements that further include additional metal components, to methods for making such catalysts, and to methods for dehydrogenating hydrocarbons using such catalysts. One aspect of the disclosure provides a calcined dehydrogenation catalyst that includes a primary species P1 selected from the group consisting of Ga, In, TI, Ge, Sn and Pb and combinations thereof; a primary species P2 selected from the lanthanides; a promoter M1 selected from the group consisting of Ni, Pd and Pt; a promoter M2 selected from the group consisting of Li, Na, K, Rb, Cs, Be, Mg, Ca, Sr and Ba, on a silica-alumina support.

Abstract: This disclosure relates to catalyst compositions including gallium and a zirconium-based mixed oxide support, to methods for making such catalysts, and to methods for dehydrogenating hydrocarbons with such catalysts. For example, in one embodiment, a catalyst composition includes a mixed oxide support comprising at least about 50 wt. % of zirconium oxide, the mixed oxide support being present in the composition in an amount within the range of about 40 wt. % to about 99.9 wt. %; and disposed on the support, gallium, present in the composition in an amount within the range of about 0.1 wt. % to about 30 wt. %, calculated as Ga2O3 on a calcined basis.

Abstract: The update method and the system of the network devices are disclosed herein. The Session Initiation Protocol (SIP) is used in the network device to update the system. The user doesn't need to input the username and password when the user is going to sign in the SIP server. By using the SIP to identify the user, the network device is able to login easily. The transmitted information is encrypted to make sure the security during transmission.